Drug‐Induced Liver Injury in GI Practice

Although drug‐induced liver injury (DILI) is a rare clinical event, it carries significant morbidity and mortality, leaving it as the leading cause of acute liver failure in the United States. It is one of the most challenging diagnoses encountered by gastroenterologists. The development of various...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandhu, Naemat, Navarro, Victor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193133/
https://www.ncbi.nlm.nih.gov/pubmed/32363315
http://dx.doi.org/10.1002/hep4.1503
_version_ 1783528134239322112
author Sandhu, Naemat
Navarro, Victor
author_facet Sandhu, Naemat
Navarro, Victor
author_sort Sandhu, Naemat
collection PubMed
description Although drug‐induced liver injury (DILI) is a rare clinical event, it carries significant morbidity and mortality, leaving it as the leading cause of acute liver failure in the United States. It is one of the most challenging diagnoses encountered by gastroenterologists. The development of various drug injury networks has played a vital role in expanding our knowledge regarding drug‐related and herbal and dietary supplement–related liver injury. In this review, we discuss what defines liver injury, epidemiology of DILI, its biochemical and pathologic patterns, and management.
format Online
Article
Text
id pubmed-7193133
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-71931332020-05-01 Drug‐Induced Liver Injury in GI Practice Sandhu, Naemat Navarro, Victor Hepatol Commun Review Although drug‐induced liver injury (DILI) is a rare clinical event, it carries significant morbidity and mortality, leaving it as the leading cause of acute liver failure in the United States. It is one of the most challenging diagnoses encountered by gastroenterologists. The development of various drug injury networks has played a vital role in expanding our knowledge regarding drug‐related and herbal and dietary supplement–related liver injury. In this review, we discuss what defines liver injury, epidemiology of DILI, its biochemical and pathologic patterns, and management. John Wiley and Sons Inc. 2020-03-13 /pmc/articles/PMC7193133/ /pubmed/32363315 http://dx.doi.org/10.1002/hep4.1503 Text en © 2020 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Review
Sandhu, Naemat
Navarro, Victor
Drug‐Induced Liver Injury in GI Practice
title Drug‐Induced Liver Injury in GI Practice
title_full Drug‐Induced Liver Injury in GI Practice
title_fullStr Drug‐Induced Liver Injury in GI Practice
title_full_unstemmed Drug‐Induced Liver Injury in GI Practice
title_short Drug‐Induced Liver Injury in GI Practice
title_sort drug‐induced liver injury in gi practice
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193133/
https://www.ncbi.nlm.nih.gov/pubmed/32363315
http://dx.doi.org/10.1002/hep4.1503
work_keys_str_mv AT sandhunaemat druginducedliverinjuryingipractice
AT navarrovictor druginducedliverinjuryingipractice

Ejemplares similares